Drug Profile

Anti-CD22 CAR NK cell therapy - Allife Medical Science and Technology

Alternative Names: Anti-CD22 chimeric antigen receptor NK cells - Allife Medical Science and Technology

Latest Information Update: 28 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allife Medical Science and Technology
Class CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Nov 2022 No recent reports of development identified for preclinical development in B-cell lymphoma in Unknown (Parenteral, Injection)
04 Oct 2018 Preclinical trials in B-cell lymphoma (Parenteral)
04 Oct 2018 Allife Medical Science and Technology plans a phase I trial for B-Cell Lymphoma (Second-line therapy or greater, Refractory metastatic disease) in November 2018 (CD22 CAR NK-BJZL-01; NCT03692767)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com